Trial Profile
Intermediate-cyclophosphamide and bortezomib for peripheral blood stem cell mobilization in multiple myeloma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Filgrastim; Lenograstim
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms IDCY-BOR PBSCH
- 23 Aug 2013 New trial record